Raymond James Financial
CARM

Raymond James Financial’s Carisma Therapeutics CARM Stock Holding History

Raymond James Financial’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-75
Closed -$29 – 5246
2025
Q2 		$29 Buy
+75
New +$20 ﹤0.01% 6910

Other funds holding CARM

MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
EF
Empowered Funds Havertown, Pennsylvania $15.7B AUM 34.02% 1-Year Est. Return

Raymond James Financial's CARM Position: Q3 2025 in Review

Raymond James Financial sold out of Carisma Therapeutics (CARM) in Q3 2025, closing a stake of 75 shares — an estimated $29 sold.

Raymond James Financial first reported a position in CARM in Q2 2025 and held it in 1 quarter. The position peaked at $29 in Q2 2025. 33 funds tracked by Wall St. Rank hold CARM as of Q3 2025.

  • Raymond James Financial reported no remaining Carisma Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 75 Carisma Therapeutics shares in Q3 2025, an estimated $29.
  • Raymond James Financial first reported a position in Carisma Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Carisma Therapeutics position peaked at $29 in Q2 2025.
  • 33 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.